Wedbush Maintains Outperform on Alpine Immune Sciences, Raises Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll maintains an Outperform rating on Alpine Immune Sciences (NASDAQ:ALPN) and raises the price target from $19 to $26.
November 03, 2023 | 1:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst maintains Outperform rating on Alpine Immune Sciences and raises the price target from $19 to $26. This could potentially lead to an increase in the stock's price.
The Outperform rating indicates that the analyst expects the company to do well compared to the broader market. The increase in the price target suggests that the analyst believes the stock is undervalued at its current price. This could lead to increased investor interest and a potential increase in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100